Ionis Pharmaceuticals (NASDAQ:IONS) Stock Falls 7.3% After Analyst Downgrade

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) shares dropped 7.3% during mid-day trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $58.00 to $41.00. The Goldman Sachs Group currently has a neutral rating on the stock. Ionis Pharmaceuticals traded as low as $29.21 and last traded at $28.7480. Approximately 978,814 shares changed hands during trading, a decline of 64% from the average daily volume of 2,736,926 shares. The stock had previously closed at $31.00.

A number of other analysts have also issued reports on the stock. Oppenheimer dropped their price objective on shares of Ionis Pharmaceuticals from $85.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday. Guggenheim reduced their target price on Ionis Pharmaceuticals from $89.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, September 15th. HC Wainwright decreased their price target on shares of Ionis Pharmaceuticals from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, October 15th. Finally, Wall Street Zen downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Nineteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Check Out Our Latest Analysis on Ionis Pharmaceuticals

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Shannon Devers sold 1,357 shares of the business’s stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the sale, the executive vice president owned 17,811 shares of the company’s stock, valued at $775,490.94. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals News Roundup

Here’s some of the latest news about IONS:

  • Neutral Sentiment: Ionis reported third-quarter revenue of $242.7 million and a loss of $0.66 per share, both better than analyst expectations. The positive earnings comparison has not offset concern about the outlook. Ionis reports third-quarter results
  • Negative Sentiment: Several analysts cut price targets following the results, including Goldman Sachs, which moved to Neutral. Although most cited firms retained Buy or Outperform ratings, the broad reductions signal a reset in expectations. Oppenheimer lowers its price target
  • Negative Sentiment: Law firms announced investigations into potential investor claims involving Ionis. These announcements add reputational uncertainty, though they do not establish wrongdoing. Investor investigation announcement

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Edmond DE Rothschild Holding S.A. increased its stake in Ionis Pharmaceuticals by 29.1% in the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 146,320 shares of the company’s stock worth $6,533,000 after purchasing an additional 33,000 shares in the last quarter. GW&K Investment Management LLC boosted its position in Ionis Pharmaceuticals by 79.6% during the third quarter. GW&K Investment Management LLC now owns 1,341,315 shares of the company’s stock valued at $59,890,000 after purchasing an additional 594,349 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter valued at about $644,000. Public Sector Pension Investment Board acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $4,276,000. Finally, Edgestream Partners L.P. bought a new stake in Ionis Pharmaceuticals in the third quarter worth $807,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Stock Performance

The company has a market cap of $4.72 billion, a P/E ratio of -8.53 and a beta of 0.43. The company has a debt-to-equity ratio of 3.42, a quick ratio of 7.73 and a current ratio of 5.43. The firm has a 50 day moving average price of $44.91 and a 200-day moving average price of $65.10.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The company had revenue of $242.72 million for the quarter, compared to the consensus estimate of $178.17 million. During the same quarter last year, the company posted ($0.80) earnings per share. The company’s revenue for the quarter was up 54.8% compared to the same quarter last year. On average, research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.61 EPS for the current year.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

See Also

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.